NanoViricides Comments on New FDA COVID Vaccine Policy

Dr. Anil Diwan, President of NanoViricides, praised the US FDA's new COVID vaccine booster policy. The policy focuses on groups at higher risk, such as adults over 65 and individuals with co-morbidities, for repeat vaccinations. This contrasts with previous broad recommendations for all ages above six months.

The FDA now emphasizes evidence-based decisions, requiring randomized, placebo-controlled trials for low-risk groups. Only 25% of eligible individuals took the vaccine in recent years, highlighting public hesitance towards vaccine uptake.

The FDA's updated stance aligns with developed countries' approaches. Dr. Diwan believes a highly effective antiviral drug could reduce the need for vaccines significantly. NanoViricides is advancing NV-387, a broad-spectrum antiviral, targeting multiple viral infections.